FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Current Opinion in Oncology

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00001622-200403000-00003PMID 15075899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Utility of FDG-PET scanning in lymphoma by WHO classification.

  2003cited by this paper
• PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma

  2003cited by this paper
• Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.

  2003cited by this paper
• Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

  2003cited by this paper
• Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT.

  2003cited by this paper
• Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

  2002cited by this paper
• Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

  2002cited by this paper
• PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

  2002cited by this paper
• Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma

  2002cited by this paper
• Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

  2002cited by this paper
• Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.

  2002cited by this paper
• Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma

  2002cited by this paper
• Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

  2001cited by this paper
• Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma

  2001cited by this paper
• Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

  2001cited by this paper
• Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.

  2001cited by this paper
• 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

  2001cited by this paper
• Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.

  2000cited by this paper
• Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

  2000cited by this paper
• Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.

  2000cited by this paper
• 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT

  2000cited by this paper
• The role of positron emission tomography (PET) in the management of lymphoma patients.

  1999cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

  1999cited by this paper
• Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

  1999cited by this paper
• Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.

  1998cited by this paper
• VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

  1998cited by this paper
• Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.

  1998cited by this paper
• High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.

  1997cited by this paper
• Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

  1995cited by this paper
• Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.

  1995cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.

  1988cited by this paper
• High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

  1987cited by this paper

• PERCISTence: Strength or Stubbornness?

  2020cites this paper
• Imaging

  2020cites this paper
• Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma.

  2013cites this paper
• Radionuclide Bone Marrow Imaging in Cancer Patients

  2012cites this paper
• High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging

  2010cites this paper
• Evaluación de la respuesta terapéutica y PET-TAC: ¿realmente sólo importa el tamaño?

  2010cites this paper
• [CT-PET and evaluation of therapy response. is the size really important?].

  2010cites this paper
• The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma

  2009cites this paper
• From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

  2009cites this paper
• [Neurolymphomatosis: diagnosis of extension and assessment of response to treatment with PET-CT].

  2009cites this paper
• FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma

  2008cites this paper
• Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET

  2008cites this paper
• Early interim PET scan in Hodgkin lymphoma: Where do we stand?

  2008cites this paper
• Value of Bone Scan in Addition to F-18 FDG PET/CT and Characteristics of Discordant Lesions between F-18 FDG PET/CT and Bone Scan in the Spinal Bony Metastasis.

  2008cites this paper
• Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.

  2007cites this paper
• Normal and Abnormal Patterns of (18)F-Fluorodeoxyglucose PET/CT in Lymphoma.

  2006cites this paper
• Resolution of SUNCT after removal of a pituitary adenoma in mild acromegaly

  2006cites this paper
• Chapter 31 – Non-Hodgkin's Lymphomas of Childhood

  2006cites this paper
• An uncommon clinical presentation of retroperitoneal non-Hodgkin lymphoma successfully treated with chemotherapy: a case report.

  2005cites this paper